BioSpace News Archive

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will release financial results for the third quarter ended September 30, 2020 after the market closes on November 9, 2020.

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) is pleased to announce that it will be offering rights (the “Rights Offering”) to holders of its common shares (“Common Shares”) of record at the close of business on October 27, 2020 (the “Record Date”)

Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development, announced the results of an experimental study of its ARDS-003 investigational new drug in a model of lung injury.

AllMed Healthcare Management, Inc., a leading provider of utilization management (UM) and independent review (IRO) services, announced today the expanded support for initial clinical reviews.

RxCap’s new consumer app will feature reminders, an adherence tracker and FDB Meducation® content, offering patients digital access to their medication list and instructions

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors

Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the acute results from the DISRUPT PAD III randomized study have been accepted for presentation in a late-breaking session at VIVA20, being held virtually from November 6-8, 2020.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP0367/MA-0211 (“ASP0367") as a potential treatment for primary mitochondrial myopathies (PMM).

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), today announced that the Company’s U.S. manufacturer, Pharmaceutics International, Inc. (“Pii”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme